For patients in early 2026 who are left with "Double Vision" (diplopia) after the inflammatory phase has passed, "Adjustable Suture Strabismus Surgery" is the gold standard for restoring "Single Vision." In early 2026, this technique allow the surgeon to "Fine-Tune" the position of the eye muscles a few hours after the initial operation while the patient is awake and can report on their vision....
A major hurdle for thyroid eye disease patients has historically been the burden of frequent hospital-based infusions, but late 2025 is seeing a breakthrough in subcutaneous (SC) delivery. Manufacturers are developing high-concentration formulations that allow patients to receive their medication via a simple injection under the skin, potentially even at home. This shift is designed to improve...
A major 2026 trend in the TED space is the move away from time-consuming intravenous infusions toward user-friendly subcutaneous (SC) delivery. In 2026, the market is identifying "Subcutaneous Biologics" as a critical value-shifter for the Thyroid Eye Disease Market, with pivotal Phase 3 data for elegrobart (VRDN-003) expected in early 2026. This 2026 movement is critical because it addresses...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
คลิกดาวน์โหลด
thai 
English
French
Spanish
Portuguese
Italiano
Romaian
Portuguese (Brazil)
china